Crinetics Pharmaceuticals Files 8-K

TL;DR

CRNX filed an 8-K on 9/26 for events on 9/25 - check for Reg FD, other events, and financials.

AI Summary

Crinetics Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting events as of September 25, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located at 6055 Lusk Boulevard, San Diego, California.

Why It Matters

This 8-K filing provides updates on Crinetics Pharmaceuticals' corporate events and financial disclosures, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not appear to contain any immediately alarming information.

Key Players & Entities

• Crinetics Pharmaceuticals, Inc. (company) — Registrant
• September 25, 2025 (date) — Date of earliest event reported
• September 26, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• 6055 Lusk Boulevard, San Diego, California 92121 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select Mar

Filing Documents

• crnx-20250925.htm (8-K) — 28KB
• crnx-2025925ex991.htm (EX-99.1) — 32KB
• img113038668_0.jpg (GRAPHIC) — 138KB
• 0001658247-25-000008.txt ( ) — 373KB
• crnx-20250925.xsd (EX-101.SCH) — 2KB
• crnx-20250925_lab.xml (EX-101.LAB) — 21KB
• crnx-20250925_pre.xml (EX-101.PRE) — 12KB
• crnx-20250925_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 25, 2025, Crinetics Pharmaceuticals, Inc. (the "Company," "Crinetics," "we," "us," or "our") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") approved PALSONIFY TM (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide ("SST2") agonist, is now the first once-daily, oral treatment approved for adults with acromegaly. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company intends to hold an investor conference call on September 25, 2025 at 6:00 pm Eastern Time to discuss the FDA approval of PALSONIFY. The press release, as well as a replay of the investor conference call, will also be available under the "Investors" section of the Company's website. The information contained in this Item 7.01 of this Current Report on Form 8-K, including in Exhibit 99.1 hereto, is being "furnished" and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On September 25, 2025, the FDA approved PALSONIFY for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide ("SST2") agonist, is now the first once-daily, oral treatment approved for adults with acromegaly. This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission ("SEC"). The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: September 25, 2025 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR